The prognosis of pancreatic cancer (PC) is one of the poorest among all cancers, due largely to the lack of methods for screening and early detection. New biomarkers for identifying high-risk or early-stage subjects could significantly impact PC mortality. Serum profiles of PC patients to healthy control subjects were compared and metabolic biomarkers associated with PC were found by using a comprehensive metabolomics technology.
